Answers are grounded in this paper and cite their sources.
Background Human papillomavirus (HPV) vaccination provides direct protection to vaccinated individuals, but also indirectly protects unvaccinated individuals through reduced HPV transmission. Mechanistic transmission models that predict the magnitude of such effects have been crucial to informing vaccination strategies. However, nearly two decades of post-vaccination experience in high-income countries now allow us to empirically characterise how population-level indirect effects vary with vaccine coverage, time since vaccine introduction, and age. Methods We synthesised studies reporting HPV16/18 prevalence before and after vaccine introduction in high-income settings between 2007 and 2025. Indirect effects were estimated as the observed reduction in HPV16/18 prevalence after accounting for expected direct vaccine protection. We used a Bayesian hierarchical model to examine associations with vaccine coverage, time since vaccine introduction, and age at effect assessment across routine, catch-up, and non-targeted vaccination groups. XGBoost was used as a complementary, non-parametric approach. Findings Data from 11 high-income settings were included. Indirect effects increased during the first five to eight years after vaccine introduction and then remained relatively stable. Indirect effects generally decreased with increasing vaccine coverage. Patterns with age differed across vaccination groups. In the routine group, indirect effects increased during adolescence and remained positive at older observed ages. In the catch-up group, indirect effects decreased with age and approached zero or became negative after approximately age 25 years. XGBoost identified similar non-linear patterns. Interpretation Indirect protection against HPV16/18 develops gradually after vaccine introduction and varies with vaccine coverage, age, and vaccination group. This empirical approach can complement transmission models by using real-world evidence to characterise population-level indirect protection. However, making predictions outside the populations and ranges represented in the data should be done cautiously.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: